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Prosthetic heart valve thrombosis is one of the most dreaded complications of mechanical heart 
valves. Suboptimal anticoagulation is the major risk for developing prosthetic heart valve thrombosis. 
Prosthetic heart valve thrombosis usually presents with dyspnea or embolic events1.
We present patient with prosthetic heart valve thrombosis without any symptoms, diagnosed via 
transthoracic echocardiography twenty days after mitral valve replacement during regular echocar-
diograph follow-up. In the medical history we obtained the information that the patient didn’t take 
anticoagulation drugs for five days after hospital discharge. Tran-
sthoracic echocardiography control revealed reduced leaflet mo-
bility and high transvalvular gradients: MV maxPG 22mmHg, MV 
meanPG 12mmHg (Figure 1). Transesophageal echocardiography 
showed the presence of thrombus on prosthetic valve measuring 
11x7 mm. Patient was readmitted to the hospital and treated with 
thrombolytic drug alteplase. According to the American College 
of Cardiology/American Heart Association Guidelines fibrinoly-
sis can be considered in a thrombosed left-sided prosthetic heart 
valve, which is of recent onset (<14 days) with class I-II symptoms 
and a small thrombus on transesophageal echocardiography. 
Control echocardiography after treatment (Figure 2) showed MV 
meanPG 3.9mmHg and normal mobility of mitral valve. Success-
ful thrombolytic therapy was followed by warfarin and intrave-
nous unfractionated heparin until the INR is 3-4. 
Current American College of Cardiology/American Heart Associa-
tion Guidelines assign Class I recommendation to transthoracic 
echocardiography or transesophageal echocardiography imaging 
in patient with prosthetic valve only in the 
presence of clinical symptoms or sings of 
valve dysfunction. Pathological studies 
and observational registries indicate that 
the risk of valve thrombosis highest in the 
first 3 month after surgical implantation of 
prosthetic valve, suggesting that antico-
agulant thromboprophylaxis in this time 
frame may be beneficial.2 Early follow up 
after surgical implantation is important 
because early detection and treatment of 
thrombus formation may lead to short-
term reduction in the risk of TE events and 
long-term prevention of prosthetic valve 
degeneration. 
Figure 1. transthoracic echocardiography control revealed 
reduced leaflet mobility and high transvalvular gradients: Mv 
maxPG 22mmHg, Mv meanPG 12.3mmHg.
Figure 2. control echocardiography after treatment 
showed: Mv maxPG 10mmHg, Mv mean PG 3.9mmHg.
